Healthcare | May 08, 2026
Vijaya Diagnostic Q4FY26 revenue jumps 27%, EBITDA margin expands to 43.5%
With robust FY26 growth, plans AI-led diagnostics and genomic testing expansion
With robust FY26 growth, plans AI-led diagnostics and genomic testing expansion
FY26 revenue rises 17% to Rs. 5,453 crore as US generics business jumps 49% and adjusted EBITDA margin improves to 26% for the quarter
The company reported robust revenue and profit growth for FY26, supported by strong CDMO performance, improving margins, and expansion across advanced manufacturing platforms
The company posted revenue of Rs. 703 crore in Q4 FY26
Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities
The figures highlight double-digit revenue growth, margin expansion, and continued momentum in complex generics and peptides CDMO platform
The company reported consolidated total income of Rs. 161.3 crore in Q4 FY26, a strong jump from Rs. 120.3 crore in the same period last year
Rs. 40 cr buyback, 200% dividend announced
Analysts expect modest revenue growth but pressure on profitability in the March quarter
Subscribe To Our Newsletter & Stay Updated
